Trial Profile
An Open-Label, Multi-Center, Single-Arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 26 Apr 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 26 Apr 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2024.
- 17 Dec 2020 Planned primary completion date changed from 31 Dec 2022 to 30 Dec 2022.